InterPAD - DETAILS

Dubermatinib, 1341200-45-0, TP-0903, TP0903, 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide, TP 0903, Dubermatinib [USAN], CHEMBL2022968, HCl-2084, compound 13, 14D65TV20J, 2-[[5-chloro-2-[4-[(4-methylpiperazin-1-yl)methyl]anilino]pyrimidin-4-yl]amino]-N,N-dimethylbenzenesulfonamide, 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide, YUAALFPUEOYPNX-UHFFFAOYSA-N, 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzenesulfonamide, DUBERMATINIB [INN], DUBERMATINIB [WHO-DD], UNII-14D65TV20J, GTPL8863, SCHEMBL12813478, EX-A609, AMY10826, BCP15884, BDBM50382425, MFCD28502172, NSC798200, WHO 10925, AKOS026750306, CCG-269819, CS-4281, DB15187, NSC-798200, SB17174, NCGC00481577-01, AC-30945, AS-55868, DA-45909, HY-12963, FT-0700169, S7846, A900291, J-690134, Q27089011, 2-((5Chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide, 35-CHLORO-N,N,74-TRIMETHYL-2,4-DIAZA-3(4,2)-PYRIMIDINA-7(1)-PIPERAZINA-1(1),5(1,4)-DIBENZENAHEPTAPHANE-12-SULFONAMIDE, BENZENESULFONAMIDE, 2-((5-CHLORO-2-((4-((4-METHYL-1-PIPERAZINYL)METHYL)PHENYL)AMINO)-4-PYRIMIDINYL)AMINO)-N,N-DIMETHYL-

No.	Title	Href
1	Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate. Sci Rep. 2024 Jan 3;14(1):425. doi: 10.1038/s41598-023-50710-3.	`Click`

No.

Title

Href

Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate. Sci Rep. 2024 Jan 3;14(1):425. doi: 10.1038/s41598-023-50710-3.

Click

Name	TP-0903
PubChem CID	56839178
Molecular Weight	516.1g/mol
Synonyms	Dubermatinib, 1341200-45-0, TP-0903, TP0903, 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide, TP 0903, Dubermatinib [USAN], CHEMBL2022968, HCl-2084, compound 13, 14D65TV20J, 2-[[5-chloro-2-[4-[(4-methylpiperazin-1-yl)methyl]anilino]pyrimidin-4-yl]amino]-N,N-dimethylbenzenesulfonamide, 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide, YUAALFPUEOYPNX-UHFFFAOYSA-N, 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzenesulfonamide, DUBERMATINIB [INN], DUBERMATINIB [WHO-DD], UNII-14D65TV20J, GTPL8863, SCHEMBL12813478, EX-A609, AMY10826, BCP15884, BDBM50382425, MFCD28502172, NSC798200, WHO 10925, AKOS026750306, CCG-269819, CS-4281, DB15187, NSC-798200, SB17174, NCGC00481577-01, AC-30945, AS-55868, DA-45909, HY-12963, FT-0700169, S7846, A900291, J-690134, Q27089011, 2-((5Chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide, 35-CHLORO-N,N,74-TRIMETHYL-2,4-DIAZA-3(4,2)-PYRIMIDINA-7(1)-PIPERAZINA-1(1),5(1,4)-DIBENZENAHEPTAPHANE-12-SULFONAMIDE, BENZENESULFONAMIDE, 2-((5-CHLORO-2-((4-((4-METHYL-1-PIPERAZINYL)METHYL)PHENYL)AMINO)-4-PYRIMIDINYL)AMINO)-N,N-DIMETHYL-
Drug Type	Small molecule
Formula	C₂₄H₃₀ClN₇O₂S
SMILES	CN1CCN(CC1)CC2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)N(C)C)Cl
InChI	1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29)
InChIKey	YUAALFPUEOYPNX-UHFFFAOYSA-N
CAS Number	1341200-45-0
ChEMBL ID	CHEMBL2022968
TTD ID	D00LGR
Drug Bank ID	DB15187
KEGG ID	D11732
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Artesunate, TP-0903
Partner Name	Artesunate
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->DNA damage and cell death
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Activity	CDH3	hsa1001
	Down-regulation	Expression	GPX8	hsa493869
	Up-regulation	Phosphorylation	H2AX	hsa3014
	Down-regulation	Expression	SOD2	hsa6648
	Down-regulation	Expression	ZEB1	hsa6935
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	T-47D	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0553
	ZR-75-1	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0588
	SK-BR-3	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0033
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
	MDA-MB-436	Invasive breast carcinoma	Homo sapiens (Human)	CVCL_0623
	BT-549	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_1092
	HBL-100	Healthy	Homo sapiens (Human)	CVCL_4362
	MCF-10A	Healthy	Homo sapiens (Human)	CVCL_0598
Result	Synergistic interactions between TP-0903 and ART indicate that combination approaches involving these compounds can have therapeutic prospects for TNBC treatment.